University of Notre Dame DU Lac Purchases New Position in Zimmer Biomet Holdings, Inc. (ZBH)

University of Notre Dame DU Lac purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,578 shares of the medical equipment provider’s stock, valued at approximately $2,644,000.

Several other institutional investors have also modified their holdings of the company. CWA Asset Management Group LLC raised its position in shares of Zimmer Biomet by 1.8% during the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 34 shares during the period. Advisory Services Network LLC raised its position in shares of Zimmer Biomet by 1.0% during the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after purchasing an additional 37 shares during the period. Palladium Partners LLC raised its position in shares of Zimmer Biomet by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 2,501 shares of the medical equipment provider’s stock valued at $321,000 after purchasing an additional 41 shares during the period. Armor Investment Advisors LLC raised its position in shares of Zimmer Biomet by 2.0% during the 2nd quarter. Armor Investment Advisors LLC now owns 2,600 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 50 shares during the period. Finally, Geneva Advisors LLC raised its position in shares of Zimmer Biomet by 2.7% during the 2nd quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after purchasing an additional 55 shares during the period. Institutional investors and hedge funds own 86.24% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded up $0.67 during midday trading on Wednesday, reaching $115.49. 1,261,000 shares of the company’s stock were exchanged, compared to its average volume of 1,358,476. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. The company has a market cap of $23,247.96, a P/E ratio of 14.23, a P/E/G ratio of 1.78 and a beta of 1.15. Zimmer Biomet Holdings, Inc. has a one year low of $100.69 and a one year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.79 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

ZBH has been the topic of several recent analyst reports. Jefferies Group restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Gabelli initiated coverage on shares of Zimmer Biomet in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective on the stock. Oppenheimer set a $137.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Monday, August 14th. SunTrust Banks set a $136.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Edward Jones upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $133.71.

WARNING: “University of Notre Dame DU Lac Purchases New Position in Zimmer Biomet Holdings, Inc. (ZBH)” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/06/university-of-notre-dame-du-lac-purchases-new-position-in-zimmer-biomet-holdings-inc-zbh.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply